{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:53:02Z","timestamp":1789228382782,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      To evaluate\n                      <jats:styled-content style=\"fixed-case\">GI<\/jats:styled-content>\n                      safety of celecoxib compared with 2 nonselective (ns)\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      s, as a secondary objective of a large trial examining multiorgan safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This randomised, double\u2010blind controlled trial analysed 24 081 patients. Osteoarthritis or rheumatoid arthritis patients, needing ongoing\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      treatment, were randomised to receive celecoxib 100\u2010200 mg b.d., ibuprofen 600\u2010800 mg t.d.s. or naproxen 375\u2010500 mg b.d. plus esomeprazole, and low\u2010dose aspirin or corticosteroids if already prescribed. Clinically significant\n                      <jats:styled-content style=\"fixed-case\">GI<\/jats:styled-content>\n                      events (\n                      <jats:styled-content style=\"fixed-case\">CSGIE<\/jats:styled-content>\n                      \u2014bleeding, obstruction, perforation events from stomach downwards or symptomatic ulcers) and iron deficiency anaemia (\n                      <jats:styled-content style=\"fixed-case\">IDA<\/jats:styled-content>\n                      ) were adjudicated blindly.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean treatment and follow\u2010up durations were 20.3 and 34.1 months. While on treatment or 30 days after,\n                      <jats:styled-content style=\"fixed-case\">CSGIE<\/jats:styled-content>\n                      occurred in 0.34%, 0.74% and 0.66% taking celecoxib, ibuprofen and naproxen. Hazard ratios (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      ) were 0.43 (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      0.27\u20100.68,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0003) celecoxib vs ibuprofen and 0.51 (0.32\u20100.81,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.004) vs naproxen. There was also less\n                      <jats:styled-content style=\"fixed-case\">IDA<\/jats:styled-content>\n                      on celecoxib:\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      0.43 (0.27\u20100.68,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0003) vs ibuprofen; 0.40 (0.25\u20100.62,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001) vs naproxen. Even taken with low\u2010dose aspirin, fewer\n                      <jats:styled-content style=\"fixed-case\">CSGIE<\/jats:styled-content>\n                      occurred on celecoxib than ibuprofen (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      0.52 [0.29\u20100.94],\n                      <jats:italic>P<\/jats:italic>\n                      = 0.03), and less\n                      <jats:styled-content style=\"fixed-case\">IDA<\/jats:styled-content>\n                      vs naproxen (0.42 [0.23\u20100.77,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005]). Corticosteroid use increased total\n                      <jats:styled-content style=\"fixed-case\">GI<\/jats:styled-content>\n                      events and\n                      <jats:styled-content style=\"fixed-case\">CSGIE<\/jats:styled-content>\n                      .\n                      <jats:italic>H. pylori<\/jats:italic>\n                      serological status had no influence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Arthritis patients taking\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      s plus esomeprazole have infrequent clinically significant gastrointestinal events. Co\u2010prescribed with esomeprazole, celecoxib has better overall\n                      <jats:styled-content style=\"fixed-case\">GI<\/jats:styled-content>\n                      safety than ibuprofen or naproxen at these doses, despite treatment with low\u2010dose aspirin or corticosteroids.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.14610","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T01:01:30Z","timestamp":1524013290000},"page":"1453-1463","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the\n                    <scp>PRECISION<\/scp>\n                    trial"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9870-832X","authenticated-orcid":false,"given":"N. D.","family":"Yeomans","sequence":"first","affiliation":[{"name":"Department of Medicine Austin Hospital University of Melbourne Melbourne Victoria Australia"},{"name":"Western Sydney University Campbelltown NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6908-8317","authenticated-orcid":false,"given":"D. Y.","family":"Graham","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine Veterans Affairs Medical Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Husni","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. H.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Harvard Medical School Brigham and Women's Hospital Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Stevens","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vargo","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Wang","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. M.","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. E.","family":"Wolski","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Borer","sequence":"additional","affiliation":[{"name":"Downstate College of Medicine State University of New York New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Libby","sequence":"additional","affiliation":[{"name":"Harvard Medical School Brigham and Women's Hospital Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Lincoff","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. F.","family":"L\u00fcscher","sequence":"additional","affiliation":[{"name":"Cardiology University Heart Center University Hospital Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Bao","sequence":"additional","affiliation":[{"name":"Pfizer New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Walker","sequence":"additional","affiliation":[{"name":"Pfizer Ltd Tadworth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. E.","family":"Nissen","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PRECISION investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.467"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30981-9"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00203-9"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70334-3"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02332-6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60673-3"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw387"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e328349de81"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611593"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.12.014"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021907"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13642"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.09.054"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16893-1"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel223"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-9-735"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.06.007"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00603-2"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90667-2"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090168"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00619-6"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07272-0"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803123381104"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.490"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2000.02267.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.14610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.14610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T13:41:41Z","timestamp":1694958101000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/apt.14610"],"URL":"https:\/\/doi.org\/10.1111\/apt.14610","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"2017-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}